施贵宝(BMY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BMY 施贵宝

未开盘 09-28 16:00:00 EDT

63.88

+1.02

+1.62%

盘后63.90

+0.02+0.03%

19:58 EDT

最高63.93	最低62.30	成交量1,402万
今开62.77	昨收62.86	日振幅2.59%
总市值1,300亿	流通市值1,298亿	总股本20.36亿
成交额8.90亿	换手率0.69%	流通股本20.32亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BMY","market":"US","secType":"STK","nameCN":"施贵宝","latestPrice":63.88,"timestamp":1790625600000,"preClose":62.86,"halted":0,"volume":14018612,"hourTrading":{"tag":"盘后","latestPrice":63.9,"preClose":63.88,"latestTime":"19:58 EDT","volume":2002137,"amount":127896193.9365,"timestamp":1790639937241,"change":0.02,"changeRate":0.000313,"amplitude":0.005103},"delay":0,"changeRate":0.01622653515749289,"floatShares":2031646263,"shares":2035753027,"eps":4.542906,"marketStatus":"未开盘","change":1.02,"latestTime":"09-28 16:00:00 EDT","open":62.77,"high":63.93,"low":62.3,"amount":890362505.834232,"amplitude":0.025931,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":4.542906,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1790668800000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":-18475200000,"exchange":"NYSE","adjPreClose":62.86,"dividendRate":0.0393,"preHourTrading":{"tag":"盘前","latestPrice":62.94,"preClose":62.86,"latestTime":"09:28 EDT","volume":3642,"amount":229715.10738,"timestamp":1790602138987,"change":0.08,"changeRate":0.001273,"amplitude":0.017162},"postHourTrading":{"tag":"盘后","latestPrice":63.9,"preClose":63.88,"latestTime":"19:58 EDT","volume":2002137,"amount":127896193.9365,"timestamp":1790639937241,"change":0.02,"changeRate":0.000313,"amplitude":0.005103},"volumeRatio":1.103894,"optionData":{"bulkOrders":[{"symbol":"BMY","call":false,"expireDate":1792123200000,"strike":"62.0","timestamp":1790611224540,"price":1.08,"volume":3000,"amount":324000,"type":"+"}]},"impliedVol":0.3085,"impliedVolPercentile":0.576},"requestUrl":"/m/hq/s/BMY","defaultTab":"news","newsList":[{"id":"1190206250","title":"百利天恒子公司获施贵宝2.5亿美元里程碑付款，伊扎-布伦协议推进顺利","url":"https://stock-news.laohu8.com/highlight/detail?id=1190206250","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190206250?lang=zh_cn&edition=full","pubTime":"2026-09-21 19:17","pubTimestamp":1789989431,"startTime":"0","endTime":"0","summary":"百利天恒宣布，其下属子公司已收到来自施贵宝的2.5亿美元里程碑付款。这笔资金与双方签署的伊扎-布伦协议相关，标志着合作项目取得阶段性重大进展。百利天恒方面表示，此次里程碑付款的落实，是两家企业深化战略伙伴关系的关键一步，同时也为创新药管线的价值释放奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0456855351.SGD","688506","LU0321505868.SGD","LU1868836914.USD","LU1323610961.USD","LU1868837136.USD","LU1670710588.SGD","LU0267386448.USD","LU1868837300.USD","BK4534","LU1883839398.USD","LU1718418525.SGD","LU2125154778.USD","IHE","LU2133065610.SGD","BK4581","LU2125154935.USD","BK4559","LU1236620750.USD","LU1571399168.USD","LU0237698245.USD","LU1291159041.SGD","LU1989771016.USD","IE00BJJMRZ35.SGD","LU1430594728.SGD","LU0061475181.USD","BK4588","LU0225284248.USD","LU1032466523.USD","FTXH","BK4585","LU0432979614.USD","IE0002141913.USD","BK0239","LU0096364046.USD","LU0225771236.USD","LU1670710661.SGD","LU2242646821.SGD","LU0868494617.USD","IE0009355771.USD","LU0985481810.HKD","LU1670711040.USD","LU1093756325.SGD","LU0306806265.USD","IE00B2B36J28.USD","LU2360032135.SGD","BK4007","LU1868836591.USD","BK4532","LU0114720955.EUR","LU1868836757.USD","LU1983299246.USD","LU2596442595.SGD","LU1585245621.USD","LU1670711123.USD","LU0306807586.USD","LU0882574055.USD","LU2242652126.USD","BMY","IE00BSNM7G36.USD","LU1261432733.SGD","IE00BFXG1179.USD","LU0321505439.SGD","LU1074936037.SGD","LU1093756168.USD","LU1236620834.HKD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668394012","title":"百时美施贵宝将于2026年10月29日公布2026年第三季度业绩。","url":"https://stock-news.laohu8.com/highlight/detail?id=2668394012","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668394012?lang=zh_cn&edition=full","pubTime":"2026-09-18 18:59","pubTimestamp":1789729172,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1093756168.USD","BK4534","LU0225284248.USD","LU0456855351.SGD","LU1074936037.SGD","LU2360032135.SGD","IE00BSNM7G36.USD","LU0237698245.USD","LU0432979614.USD","LU1883839398.USD","BMY","LU1032466523.USD","BK4007","LU0267386448.USD","BK4585","LU0114720955.EUR","LU1983299246.USD","LU2125154778.USD","BK4559","BK4581","LU1989771016.USD","IE00BFXG1179.USD","LU1718418525.SGD","LU1291159041.SGD","LU2133065610.SGD","IE0009355771.USD","IE0002141913.USD","LU1868837300.USD","LU1868836757.USD","IE00B2B36J28.USD","LU1323610961.USD","LU0985481810.HKD","LU2596442595.SGD","LU1868836914.USD","BK4588","IHE","LU0321505868.SGD","IE00BJT1NW94.SGD","LU1670710661.SGD","LU2242646821.SGD","LU1261432733.SGD","LU2242652126.USD","FTXH","LU0061475181.USD","LU0306806265.USD","LU1093756325.SGD","BK4532","LU1236620834.HKD","LU1585245621.USD","LU1571399168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668948847","title":"Piper Sandler上调百时美施贵宝目标价至82美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2668948847","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668948847?lang=zh_cn&edition=full","pubTime":"2026-09-18 14:29","pubTimestamp":1789712992,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2242646821.SGD","IE0009355771.USD","LU0114720955.EUR","LU1323610961.USD","BMY","IE00BFTCPJ56.SGD","UUP","LU0306807586.USD","LU0456855351.SGD","UDN","LU2125154935.USD","LU0096364046.USD","LU1291159041.SGD","LU1989771016.USD","LU0267386448.USD","IE00BSNM7G36.USD","BK4588","IE0002141913.USD","BK4007","LU1032466523.USD","LU1718418525.SGD","LU1670710588.SGD","LU1868836591.USD","LU2360032135.SGD","BK4585","LU1074936037.SGD","LU1868837136.USD","LU1670711123.USD","LU1983299246.USD","LU1093756325.SGD","BK4532","IE00BJT1NW94.SGD","LU0225284248.USD","LU0321505868.SGD","LU2596442595.SGD","LU0225771236.USD","LU0985481810.HKD","LU1883839398.USD","LU1868836757.USD","LU1571399168.USD","LU0321505439.SGD","BK4581","LU1670711040.USD","LU1430594728.SGD","LU1868837300.USD","LU0882574055.USD","IHE","BK4559","FTXH","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139471658","title":"施贵宝公布Sotyktu（Deucravacitinib）两年临床数据：银屑病关节炎成人患者疗效持久且安全性稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1139471658","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139471658?lang=zh_cn&edition=full","pubTime":"2026-09-17 19:00","pubTimestamp":1789642811,"startTime":"0","endTime":"0","summary":"施贵宝近日披露了其重磅药物Sotyktu的最新研究结果。数据表明，在成人银屑病关节炎患者群体中，这款口服疗法的疗效可持续长达两年之久，且其安全性特征保持一致。此番公布的临床数据，为Sotyktu在长期管理该慢性炎症性疾病方面的潜力增添了有力佐证。这进一步巩固了Deucravacitinib作为一种耐受性良好的长期治疗选项的地位。施贵宝公司表示，这些发现不仅加深了医学界对Sotyktu作用机制的理解，也为临床医生在制定长期治疗策略时提供了更为坚实的数据支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4559","LU1868837136.USD","IE00BFXG1179.USD","LU0432979614.USD","LU1291159041.SGD","BK4532","LU1323610961.USD","LU1093756168.USD","LU2242646821.SGD","LU1261432733.SGD","LU1430594728.SGD","LU1718418525.SGD","LU1883839398.USD","LU0225771236.USD","LU1093756325.SGD","LU0321505439.SGD","BK4581","LU0225284248.USD","LU1670711123.USD","LU1868836914.USD","IE0002141913.USD","BMY","IE00BJT1NW94.SGD","LU1670710661.SGD","LU0237698245.USD","LU1236620750.USD","LU2125154778.USD","LU0868494617.USD","LU1236620834.HKD","LU0114720955.EUR","BK4007","LU1571399168.USD","LU1989771016.USD","LU2360032135.SGD","LU0061475181.USD","FTXH","IE00BSNM7G36.USD","IE00BFTCPJ56.SGD","LU1868836591.USD","BK4534","LU1032466523.USD","IE0009355771.USD","LU1868837300.USD","LU1868836757.USD","BK4588","LU0306806265.USD","LU1585245621.USD","IE00B2B36J28.USD","LU0882574055.USD","LU2125154935.USD","LU2596442595.SGD","LU0321505868.SGD","IHE","LU2133065610.SGD","LU0456855351.SGD","LU0985481810.HKD","LU1670710588.SGD","LU1670711040.USD","LU0267386448.USD","BK4585","LU2242652126.USD","LU1983299246.USD","LU0096364046.USD","LU0306807586.USD","IE00BJJMRZ35.SGD","LU1074936037.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667607482","title":"百时美施贵宝公司宣布，派发季度股息，每股派0.63美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2667607482","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667607482?lang=zh_cn&edition=full","pubTime":"2026-09-16 18:59","pubTimestamp":1789556361,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1670711123.USD","LU1883839398.USD","LU2242652126.USD","VIG","IE00BJJMRZ35.SGD","LU1585245621.USD","LU1670710661.SGD","LU0306806265.USD","LU2242646821.SGD","LU1670710588.SGD","IE00BFTCPJ56.SGD","LU1670711040.USD","IE0002141913.USD","LU0225284248.USD","LU0321505439.SGD","BK4559","LU0096364046.USD","LU1236620834.HKD","LU0321505868.SGD","LU1032466523.USD","BK4581","LU1868837300.USD","LU0432979614.USD","IHE","BK4007","LU2596442595.SGD","UDN","FTXH","LU1718418525.SGD","LU0225771236.USD","UUP","LU1261432733.SGD","LU1323610961.USD","BK4534","LU1868837136.USD","LU1983299246.USD","LU1868836591.USD","IE00BJT1NW94.SGD","LU1291159041.SGD","LU1868836914.USD","LU2125154778.USD","LU0114720955.EUR","IE0009355771.USD","BK4588","LU0237698245.USD","BMY","LU0882574055.USD","LU1989771016.USD","LU1236620750.USD","IE00BFXG1179.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667267605","title":"百时美施贵宝就安进拟推出的Opdivo生物类似药提起诉讼","url":"https://stock-news.laohu8.com/highlight/detail?id=2667267605","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667267605?lang=zh_cn&edition=full","pubTime":"2026-09-16 10:15","pubTimestamp":1789524901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1023059063.AUD","XPH","LU0061475181.USD","LU0058720904.USD","LU1868836591.USD","LU2468319806.SGD","BK4533","IBBQ","IE0009355771.USD","LU2272731865.HKD","BK4534","BIB","LU1670711123.USD","LU2322448957.HKD","FTXH","AMGN","LU0868494617.USD","LU1983299246.USD","BK4585","BMY","LU1261432733.SGD","IE00BSNM7G36.USD","LU1868837300.USD","BK4559","PJP","IHE","IE00B4R5TH58.HKD","LU0289739699.SGD","BBH","LU0114720955.EUR","TBXU","LU2272731600.USD","IBB","LU0109394709.USD","LU1236620834.HKD","LU1992135399.USD","BK4139","LU0225284248.USD","PPH","LU2473716301.USD","LU0225771236.USD","BK4588","LU1883839398.USD","LU2125154778.USD","BK4566","LU1989771016.USD","PBE","LU1868836757.USD","LU0320765992.SGD","LU1236620750.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153195790","title":"异动解读｜施贵宝盘中下跌3.05%，CAR-T安全风波拖累板块抵消积极临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1153195790","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153195790?lang=zh_cn&edition=full","pubTime":"2026-09-08 21:37","pubTimestamp":1788874622,"startTime":"0","endTime":"0","summary":"9月8日，施贵宝盘中下跌3.05%，报64.575美元/股，成交额4231.81万美元。尽管公司当日宣布其潜在首创GPRC5D靶向CAR-T细胞疗法Arlocabtagene Autoleucel的注册性II期试验达到主要及关键次要终点，总缓解率与完全缓解率双双达标，但积极数据未能扭转跌势。消息面上，CAR-T领域安全风波持续发酵。制药板块整体承压，诺华当日大跌12.52%，强生跌2.91%，默沙东跌2.09%，行业性利空情绪显著压制个股表现。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"施贵宝下跌，CAR-T安全风波拖累板块","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145175985","title":"施贵宝宣布潜在首创GPRC5D靶向CAR T细胞疗法Arlocabtagene Autoleucel注册性II期关键试验取得积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1145175985","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1145175985?lang=zh_cn&edition=full","pubTime":"2026-09-08 19:00","pubTimestamp":1788865214,"startTime":"0","endTime":"0","summary":"施贵宝今日披露，其研发的潜在首创GPRC5D靶向CAR T细胞疗法——Arlocabtagene Autoleucel，在注册性II期关键试验中收获积极顶线数据。施贵宝表示，完整的试验结果将在即将召开的科学会议上进行展示，同时公司计划与全球监管机构展开沟通，以推动该疗法的临床开发进程。这一里程碑式的进展，不仅彰显了施贵宝在细胞治疗领域的深厚布局，也再次印证了精准医疗在肿瘤学中的变革潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","LU0432979614.USD","IE00BFXG1179.USD","LU0237698245.USD","LU0306806265.USD","IE00B2B36J28.USD","LU1883839398.USD","LU1291159041.SGD","LU2133065610.SGD","LU1236620834.HKD","LU0096364046.USD","IE00BJJMRZ35.SGD","LU2242646821.SGD","IHE","BK4588","LU1261432733.SGD","LU1670711040.USD","LU1323610961.USD","LU2125154778.USD","IE0002141913.USD","BK4585","LU0114720955.EUR","BMY","FTXH","LU0306807586.USD","LU2242652126.USD","BK4559","LU0985481810.HKD","LU0321505439.SGD","IE00BSNM7G36.USD","BK4581","LU0882574055.USD","LU1032466523.USD","IE0009355771.USD","LU1571399168.USD","LU1718418525.SGD","LU1983299246.USD","LU1585245621.USD","LU0456855351.SGD","LU1670710661.SGD","LU0225771236.USD","LU0321505868.SGD","LU0868494617.USD","LU1670711123.USD","LU2596442595.SGD","BK4007","LU1670710588.SGD","LU2125154935.USD","LU2360032135.SGD","LU1093756168.USD","LU1868837136.USD","LU1868837300.USD","LU1989771016.USD","LU1868836757.USD","LU1430594728.SGD","LU1868836914.USD","LU0061475181.USD","LU0267386448.USD","LU1236620750.USD","IE00BFTCPJ56.SGD","BK4532","LU1074936037.SGD","IE00BJT1NW94.SGD","LU0225284248.USD","LU1093756325.SGD","LU1868836591.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190662498","title":"施贵宝：二期临床试验达到主要终点，总缓解率与完全缓解率双双达标","url":"https://stock-news.laohu8.com/highlight/detail?id=1190662498","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190662498?lang=zh_cn&edition=full","pubTime":"2026-09-08 19:00","pubTimestamp":1788865213,"startTime":"0","endTime":"0","summary":"施贵宝公司宣布，其二期临床试验成功达成主要终点。该试验聚焦于总体缓解率及完全缓解率两项核心指标，结果均呈现积极态势，为后续研发推进奠定了坚实基础。此项临床研究的设计初衷在于评估药物在特定患者群体中的疗效表现。总体缓解率的显著提升，加之完全缓解率的亮眼数据，共同勾勒出一幅令人振奋的疗效图景。市场对此消息的反应尚待观察，但无疑，这已是公司研发管线中一颗值得期待的棋子。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1571399168.USD","LU0114720955.EUR","LU2242652126.USD","IE00BFTCPJ56.SGD","LU1883839398.USD","LU0321505439.SGD","LU1868836591.USD","IE00BSNM7G36.USD","IE00BFXG1179.USD","LU0267386448.USD","LU2125154778.USD","BK4585","IE00BJJMRZ35.SGD","LU0306806265.USD","LU2242646821.SGD","LU1670710661.SGD","LU0882574055.USD","LU0225771236.USD","BK4581","LU1868836914.USD","BK4532","LU1718418525.SGD","LU0432979614.USD","LU2596442595.SGD","LU1093756325.SGD","LU1989771016.USD","BK4559","LU2133065610.SGD","LU0456855351.SGD","LU1236620750.USD","LU1236620834.HKD","LU2360032135.SGD","BK4588","LU1868836757.USD","BK4534","IE0002141913.USD","LU0868494617.USD","LU1670711123.USD","LU2125154935.USD","BK4007","FTXH","LU0061475181.USD","LU0237698245.USD","LU1430594728.SGD","LU1261432733.SGD","LU0306807586.USD","LU1670711040.USD","LU0321505868.SGD","LU1074936037.SGD","LU0096364046.USD","LU1291159041.SGD","LU1323610961.USD","LU1868837300.USD","IHE","IE00B2B36J28.USD","LU1585245621.USD","BMY","LU0985481810.HKD","LU1670710588.SGD","LU1868837136.USD","LU1032466523.USD","IE00BJT1NW94.SGD","LU0225284248.USD","LU1983299246.USD","IE0009355771.USD","LU1093756168.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665322333","title":"百时美施贵宝：潜在同类首创药物的注册性 2 期 QUINTESSENTIAL 试验取得积极顶线结果。","url":"https://stock-news.laohu8.com/highlight/detail?id=2665322333","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665322333?lang=zh_cn&edition=full","pubTime":"2026-09-08 18:59","pubTimestamp":1788865173,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1868836914.USD","BK4585","LU1983299246.USD","LU0061475181.USD","IHE","LU2242646821.SGD","IE0009355771.USD","BK4532","FTXH","LU0456855351.SGD","BMY","LU1868837300.USD","LU2125154935.USD","LU0114720955.EUR","IE00B2B36J28.USD","LU2242652126.USD","LU0432979614.USD","LU2133065610.SGD","LU1291159041.SGD","LU0225771236.USD","LU1323610961.USD","LU1236620834.HKD","LU0267386448.USD","LU1093756168.USD","LU0306807586.USD","LU1670711040.USD","LU0237698245.USD","LU1718418525.SGD","LU1868836591.USD","LU2125154778.USD","LU0096364046.USD","LU0868494617.USD","LU0985481810.HKD","LU1236620750.USD","LU0882574055.USD","LU0306806265.USD","LU1670711123.USD","LU1430594728.SGD","LU1074936037.SGD","LU2360032135.SGD","LU1670710588.SGD","IE0002141913.USD","IE00BJT1NW94.SGD","IE00BSNM7G36.USD","LU0321505439.SGD","LU0321505868.SGD","BK4007","IE00BJJMRZ35.SGD","IE00BFTCPJ56.SGD","LU1868836757.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102122486","title":"施贵宝发言人：已主动暂停Zola-Cel项目临床数据审查","url":"https://stock-news.laohu8.com/highlight/detail?id=1102122486","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102122486?lang=zh_cn&edition=full","pubTime":"2026-09-01 19:49","pubTimestamp":1788263380,"startTime":"0","endTime":"0","summary":"施贵宝公司发言人今日表示，公司已实施一项自愿性暂停措施，旨在全面审视其Zola-Cel项目所涉及的临床数据。据悉，此次暂停并非因任何已明确的安全信号而起，而是出于对现有资料进行更为细致、系统性复核的审慎考量。通过此举，施贵宝力图确保所有临床环节均符合最高标准，从而为后续决策奠定坚实基础。目前，相关审查工作已有序展开。市场观察人士正密切关注这一动态，期望公司能在完成评估后，为Zola-Cel疗法的未来发展提供更清晰的路径指引。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2360032135.SGD","IE00BFTCPJ56.SGD","LU1868837136.USD","LU0882574055.USD","LU2596442595.SGD","LU0114720955.EUR","LU1585245621.USD","LU1571399168.USD","LU1989771016.USD","LU1868837300.USD","BK4532","LU0306806265.USD","LU0306807586.USD","LU1236620834.HKD","LU1093756168.USD","LU1291159041.SGD","LU1323610961.USD","LU0868494617.USD","LU0432979614.USD","LU2125154935.USD","BMY","LU0237698245.USD","LU0096364046.USD","LU0456855351.SGD","LU0225771236.USD","LU0267386448.USD","LU1868836591.USD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","BK4559","LU1032466523.USD","LU1670711040.USD","BK4585","IE0002141913.USD","LU1868836914.USD","LU1236620750.USD","LU1670710588.SGD","LU1670711123.USD","IE0009355771.USD","LU1670710661.SGD","IE00BFXG1179.USD","BK4007","LU0321505868.SGD","BK4534","LU1074936037.SGD","LU2242646821.SGD","IE00BSNM7G36.USD","LU0985481810.HKD","LU2133065610.SGD","IE00BJT1NW94.SGD","LU1868836757.USD","LU1430594728.SGD","BK4588","IHE","LU1983299246.USD","LU2242652126.USD","LU0321505439.SGD","LU0225284248.USD","BK4581","LU0061475181.USD","FTXH","LU2125154778.USD","LU1093756325.SGD","LU1883839398.USD","LU1261432733.SGD","LU1718418525.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663044361","title":"五年持续获益！玛伐凯泰最长随访数据公布，进一步证实在oHCM中的长期疗效与安全性","url":"https://stock-news.laohu8.com/highlight/detail?id=2663044361","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663044361?lang=zh_cn&edition=full","pubTime":"2026-08-30 18:09","pubTimestamp":1788084540,"startTime":"0","endTime":"0","summary":"\"EXPLORER-LTE 长达五年的研究数据表明，玛伐凯泰可为有症状的oHCM患者带来持续且具有临床意义的治疗获益。此次ESC大会公布的其他研究结果进一步支持了玛伐凯泰的疗效和安全性，并加深了我们对oHCM疾病影响的理解。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5035957_ZH35957_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5035957_ZH35957_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0154245756.USD","HCM","IE00BJJMRZ35.SGD","LU0985481810.HKD","IE00BJT1NW94.SGD","LU0114720955.EUR","BK4534","IE0002141913.USD","LU0225284248.USD","MADE","IE000M9KFDE8.USD","LU1868837136.USD","LU1718418525.SGD","LU0306807586.USD","LU1074936037.SGD","LU1585245621.USD","LU0882574055.USD","LU1670711123.USD","LU0267386448.USD","LU1291159041.SGD","IE00BFTCPJ56.SGD","LU2125154778.USD","LU1032466523.USD","IE00B2B36J28.USD","LU0456855351.SGD","LU0321505868.SGD","LU1093756168.USD","LU2125154935.USD","LU0237698245.USD","LU1571399168.USD","LU1670711040.USD","LU2242646821.SGD","LU2463526074.USD","IHE","BK4149","FTXH","BK4007","LU0306806265.USD","IE00BSNM7G36.USD","BK4532","LU0069063385.USD","BK4533","BK4567","BK4531","CMI","LU1983299246.USD","LU0203345920.USD","LU0203347892.USD","BMY","LU2133065610.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138479318","title":"施贵宝发言人：Cellares合作的细胞穿梭系统未能达到商业化生产Breyanzi的必要标准","url":"https://stock-news.laohu8.com/highlight/detail?id=1138479318","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138479318?lang=zh_cn&edition=full","pubTime":"2026-08-25 23:36","pubTimestamp":1787672215,"startTime":"0","endTime":"0","summary":"施贵宝发言人近日表示，经评估，与Cellares合作的细胞穿梭系统被认定无法满足生产商业化Breyanzi所需的严格要求。因此，施贵宝选择终止该项合作评估，转而寻求其他可行的生产路径，以确保Breyanzi的供应稳定性和患者可及性不受影响。施贵宝方面未透露更多技术细节，但强调将继续致力于优化生产流程，并探索多元化的合作机会，以推动其肿瘤学管线的高效落地。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFXG1179.USD","IE0002141913.USD","LU1291159041.SGD","LU0306807586.USD","LU2596442595.SGD","BK4559","LU0061475181.USD","LU1670710661.SGD","BK4588","LU0985481810.HKD","LU1983299246.USD","LU0267386448.USD","LU1093756168.USD","LU0114720955.EUR","BK4532","LU0868494617.USD","LU0225284248.USD","LU0306806265.USD","LU0882574055.USD","LU1868836757.USD","LU1670711040.USD","LU1430594728.SGD","LU2360032135.SGD","LU1989771016.USD","FTXH","IE00BFTCPJ56.SGD","LU1868837136.USD","IE00BJT1NW94.SGD","LU1074936037.SGD","LU1032466523.USD","LU0321505868.SGD","LU1261432733.SGD","BK4007","LU1883839398.USD","LU1585245621.USD","LU0225771236.USD","BK4534","LU1670710588.SGD","BK4581","LU1868836914.USD","LU2125154778.USD","LU1718418525.SGD","LU2242646821.SGD","IE00BSNM7G36.USD","IHE","LU1670711123.USD","LU1868837300.USD","LU0096364046.USD","LU0237698245.USD","LU0321505439.SGD","LU1571399168.USD","BMY","LU2133065610.SGD","IE0009355771.USD","LU0456855351.SGD","BK4585","LU2125154935.USD","IE00B2B36J28.USD","LU1093756325.SGD","LU1323610961.USD","IE00BJJMRZ35.SGD","LU1868836591.USD","LU2242652126.USD","LU0432979614.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662154755","title":"百时美施贵宝发言人确认，已终止与Cellares的合作关系。","url":"https://stock-news.laohu8.com/highlight/detail?id=2662154755","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662154755?lang=zh_cn&edition=full","pubTime":"2026-08-25 23:35","pubTimestamp":1787672120,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1261432733.SGD","LU1883839398.USD","BMY","LU2133065610.SGD","LU0114720955.EUR","IE00BJJMRZ35.SGD","LU0321505439.SGD","LU0267386448.USD","LU1989771016.USD","LU1670711123.USD","LU2242646821.SGD","LU1868836591.USD","LU0225771236.USD","LU0868494617.USD","LU2242652126.USD","BK4007","LU1718418525.SGD","LU0985481810.HKD","LU0225284248.USD","BK4559","IHE","LU1585245621.USD","LU1291159041.SGD","LU2360032135.SGD","IE0009355771.USD","IE00BFTCPJ56.SGD","LU1032466523.USD","LU1323610961.USD","LU1093756168.USD","LU0096364046.USD","LU2125154778.USD","FTXH","LU0061475181.USD","LU0432979614.USD","LU1868836914.USD","LU1983299246.USD","BK4585","LU1093756325.SGD","LU0237698245.USD","LU0456855351.SGD","IE00BSNM7G36.USD","LU2125154935.USD","LU2596442595.SGD","BK4534","IE00BFXG1179.USD","BK4581","LU1868837136.USD","IE00BJT1NW94.SGD","LU1670711040.USD","LU1670710588.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111103812","title":"异动解读｜施贵宝盘中上涨3.02%，制药板块全线走强叠加AI抗体研发合作提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1111103812","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111103812?lang=zh_cn&edition=full","pubTime":"2026-08-21 23:00","pubTimestamp":1787324442,"startTime":"0","endTime":"0","summary":"8月21日，施贵宝盘中上涨3.02%，报67.45美元/股，成交额1.58亿美元。消息面上，施贵宝近日宣布与Chai Discovery达成抗体研发合作协议，将利用Chai的AI分子折叠与设计模型加速药物发现进程，探索传统方法难以触及的靶点。同时，制药板块整体表现强劲，默沙东涨3.47%、辉瑞涨2.21%、礼来涨1.93%、强生涨1.51%，板块联动效应显著。施贵宝前一交易日曾随板块回调跌逾3%，当前反弹亦受到技术性修复推动。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"施贵宝上涨，AI抗体合作引爆制药板块","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124108304","title":"异动解读｜施贵宝盘中下跌3.03%，报65.565美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1124108304","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1124108304?lang=zh_cn&edition=full","pubTime":"2026-08-21 03:47","pubTimestamp":1787255247,"startTime":"0","endTime":"0","summary":"8月21日，施贵宝盘中下跌3.03%，报65.565美元/股，成交额4.24亿美元。施贵宝所在的制药行业整体承压，个股中，礼来跌2.7%，默沙东跌2.0%，强生跌2.01%，阿斯利康跌0.24%，Crinetics Pharmaceuticals持平。百时美施贵宝公司是一家全球性生物制药企业，专注于肿瘤学、血液学、免疫学、心血管和神经科学等领域创新药物的发现与开发，产品在全球范围内销售。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660287974","title":"百时美施贵宝与Chai Discovery合作利用AI开发新疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2660287974","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660287974?lang=zh_cn&edition=full","pubTime":"2026-08-20 21:27","pubTimestamp":1787232474,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1093756325.SGD","LU0456855351.SGD","ARTY","LU1868836591.USD","BK4585","IHE","LU2242652126.USD","LU1868837136.USD","LU1718418525.SGD","LU1093756168.USD","LU0096364046.USD","IE00BJJMRZ35.SGD","BK4532","LU1074936037.SGD","LU1989771016.USD","LU2360032135.SGD","LU0868494617.USD","BK4588","LU0321505439.SGD","AIPO","LU1032466523.USD","BK4581","BMY","LU1585245621.USD","FTXH","LU1261432733.SGD","AGIX","QTOC","CHAT","LU1868836757.USD","LU2125154778.USD","LU0306806265.USD","LU1571399168.USD","BK4007","LU0114720955.EUR","LU0985481810.HKD","LU2133065610.SGD","LU0882574055.USD","LU1670710661.SGD","IE00BFXG1179.USD","VTHR","LU0432979614.USD","LU1670711123.USD","LU0321505868.SGD","LU2242646821.SGD","LU1883839398.USD","BK4534","LU2125154935.USD","LU1291159041.SGD","IE00BSNM7G36.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660228241","title":"Chai Discovery与百时美施贵宝达成抗体研发合作协议，百时美施贵宝将使用Chai AI模型支持抗体发现。","url":"https://stock-news.laohu8.com/highlight/detail?id=2660228241","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660228241?lang=zh_cn&edition=full","pubTime":"2026-08-20 21:03","pubTimestamp":1787230989,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU1868836757.USD","QTOC","LU1093756325.SGD","LU1868836914.USD","LU1883839398.USD","FTXH","BMY","IE00BJT1NW94.SGD","LU1989771016.USD","LU1868836591.USD","LU2125154778.USD","LU1670711040.USD","LU2360032135.SGD","LU0456855351.SGD","VTHR","LU1291159041.SGD","LU1585245621.USD","LU1093756168.USD","LU0321505868.SGD","LU2596442595.SGD","BK4588","AGIX","BK4007","LU0321505439.SGD","ARTY","LU0096364046.USD","LU1670711123.USD","LU2242652126.USD","LU2133065610.SGD","LU0868494617.USD","LU0225771236.USD","LU0306806265.USD","LU0985481810.HKD","BK4534","IE0002141913.USD","IE00BSNM7G36.USD","AIPO","LU2242646821.SGD","BK4532","IHE","LU1868837300.USD","LU1074936037.SGD","IE00BFTCPJ56.SGD","IE00BFXG1179.USD","CHAT","LU0225284248.USD","LU0882574055.USD","IE00BJJMRZ35.SGD","LU1261432733.SGD","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158253265","title":"异动解读｜施贵宝盘中上涨3.11%，Zenbexus获FDA加速批准叠加制药板块走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1158253265","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158253265?lang=zh_cn&edition=full","pubTime":"2026-08-19 21:52","pubTimestamp":1787147568,"startTime":"0","endTime":"0","summary":"8月19日，施贵宝盘中上涨3.11%，报68.1美元/股，成交额1.1亿美元。消息面上，FDA于8月14日授予施贵宝首款Celmod疗法Zenbexus联合达雷妥尤单抗及地塞米松的加速批准，用于治疗至少接受过一线治疗的多发性骨髓瘤成人患者。三期临床数据显示，Zenbexus组合方案的微小残留病灶阴性完全缓解率达41%，显著优于对照组的21%。当日制药板块整体表现强劲，默沙东涨10.37%、礼来涨4.61%、辉瑞涨3.23%，板块联动效应亦对施贵宝形成提振。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659219498","title":"施贵宝iberdomide获FDA批准用于治疗多发性骨髓瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2659219498","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659219498?lang=zh_cn&edition=full","pubTime":"2026-08-14 10:28","pubTimestamp":1786674495,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU0321505868.SGD","LU1868836914.USD","LU1323610961.USD","LU1868837136.USD","LU1670710588.SGD","LU0267386448.USD","BK4534","LU1718418525.SGD","LU2125154778.USD","IHE","LU2133065610.SGD","BK4581","LU2125154935.USD","BK4559","LU0237698245.USD","LU1291159041.SGD","LU1989771016.USD","IE00BJJMRZ35.SGD","LU1430594728.SGD","LU0061475181.USD","BK4588","LU0225284248.USD","LU1032466523.USD","FTXH","LU0432979614.USD","IE0002141913.USD","LU0096364046.USD","LU0225771236.USD","LU1670710661.SGD","LU0868494617.USD","IE0009355771.USD","LU1093756325.SGD","LU0306806265.USD","IE00B2B36J28.USD","LU2360032135.SGD","LU1868836591.USD","LU1868836757.USD","LU1983299246.USD","LABU","LU0306807586.USD","LU0882574055.USD","LU2242652126.USD","BMY","IE00BSNM7G36.USD","LU1261432733.SGD","IE00BFXG1179.USD","LU1074936037.SGD","LU1093756168.USD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bms.com","stockEarnings":[{"period":"1week","weight":0.0201},{"period":"1month","weight":-0.0406},{"period":"3month","weight":0.1086},{"period":"6month","weight":0.0348},{"period":"1year","weight":0.4479},{"period":"ytd","weight":0.1843}],"compareEarnings":[{"period":"1week","weight":-0.0102},{"period":"1month","weight":-0.0049},{"period":"3month","weight":0.0252},{"period":"6month","weight":0.1684},{"period":"1year","weight":0.1568},{"period":"ytd","weight":0.1227}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"百时美施贵宝公司于1933年8月在美国德拉瓦州注册成立，源自于1887年在纽约创办的企业，并在1989年因合并而重命名。作为一家生物制药公司，百时美施贵宝专注于创新药物的发现、开发、许可、生产、营销和销售，以对抗严重疾病。公司的战略方法结合了大型制药公司的资源和规模，以及生物技术行业特有的灵活性和创新重点。百时美施贵宝优先关注肿瘤学、血液学、免疫学、心血管和神经科学等领域的变革性药物，旨在提供长期价值和竞争优势。作为全球研究型制药公司，百时美施贵宝的产品在全球范围内销售，服务于包括批发商、分销商和特药药房在内的多种实体，并在多个国家保持着重要的生产运营。","yearOnYearQuotes":[{"month":1,"riseRate":0.478261,"avgChangeRate":-0.011323},{"month":2,"riseRate":0.565217,"avgChangeRate":0.011855},{"month":3,"riseRate":0.630435,"avgChangeRate":0.007963},{"month":4,"riseRate":0.468085,"avgChangeRate":-0.005808},{"month":5,"riseRate":0.553191,"avgChangeRate":0.001393},{"month":6,"riseRate":0.617021,"avgChangeRate":0.009381},{"month":7,"riseRate":0.425532,"avgChangeRate":0.001143},{"month":8,"riseRate":0.531915,"avgChangeRate":-0.000512},{"month":9,"riseRate":0.510638,"avgChangeRate":0.008786},{"month":10,"riseRate":0.586957,"avgChangeRate":0.025121},{"month":11,"riseRate":0.630435,"avgChangeRate":0.022318},{"month":12,"riseRate":0.630435,"avgChangeRate":0.022265}],"exchange":"NYSE","name":"施贵宝","nameEN":"Bristol-Myers Squibb"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"施贵宝(BMY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供施贵宝(BMY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"施贵宝,BMY,施贵宝股票,施贵宝股票老虎,施贵宝股票老虎国际,施贵宝行情,施贵宝股票行情,施贵宝股价,施贵宝股市,施贵宝股票价格,施贵宝股票交易,施贵宝股票购买,施贵宝股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"施贵宝(BMY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供施贵宝(BMY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}